Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update

2021 Annual Meeting of Stockholders

Jun 7, 2021 • 4:00pm EDT